LAWRENCE, Mass., Sept. 8, 2015 /PRNewswire/ -- In honor of the 10th anniversary of the Food and Drug Administration's (FDA) clearance of its revolutionary System One™, NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of dialysis products, is celebrating patient milestones all summer long to promote the significant life-changing benefits made possible with home hemodialysis (HHD) and NxStage's decade-long role in helping patients live better lives.
NxStage was created more than ten years ago with the mission of improving the standard of renal care for patients. Today, the System One is the first and only portable dialysis machine that enables patients to perform hemodialysis in their homes or while traveling, during the day or at night while sleeping. It has been used to perform over twelve million treatments on thousands of patients around the world, helping change the way patients and clinicians think about hemodialysis. To learn more about NxStage's history of innovation, visit Our History of Innovation for a graphic timeline highlighting the Company's milestone clearances.
Tina Harrison, a 45 year-old Mumford, TN resident and military wife, has struggled with kidney disease since she was in high school. After experiencing total renal failure, she started in-center dialysis treatment at age 25. After more than 13 years of in-center treatment and two unsuccessful kidney transplants, she discovered HHD with the System One. She then got married and began moving to different military bases around the country as a result of her husband's military assignments, taking the System One with her wherever they went.
Now, seven years later, Tina has extensively traveled, gone trick or treating with her children, enjoyed bike rides and camping, attended family weddings, gone to her son's boot camp graduation – things she says would never have been possible without the flexibility of the System One. Tina also recently began performing more frequent home nocturnal hemodialysis with the System One which has given her more time during the day to live her life. Hear Tina's journey http://go.nxstage.com/Tina.
"The NxStage System One has given me a second life," said Tina. "I've been able to do things I never thought possible. I no longer worry about whether or not my husband's new station is close to a dialysis center – I have my machine with me wherever I go. It fits into my life."
"We're inspired by the amazing things, big and small, that our patients have been able to achieve while performing therapy with the NxStage System One," said Joseph E. Turk, president of NxStage. "We're continuing to innovate to help our patients not only live longer, but also live better lives."
Visit NxStage's Facebook page www.facebook.com/NxStage to read more inspiring patient stories throughout the summer. If you would like to share your personal achievements while using the System One please email NxStage's patient marketing team at [email protected].
For more information about the System One, home hemodialysis or home nocturnal hemodialysis, please visit www.nxstage.com.
Despite the health benefits that home hemodialysis may provide to those with chronic kidney disease, this form of therapy is not for everyone. The reported benefits of home hemodialysis may not be experienced by all patients. The risks associated with hemodialysis treatments in any environment include, but are not limited to, high blood pressure, fluid overload, low blood pressure, heart-related issues, and vascular access complications. The medical devices used in hemodialysis therapies may add additional risks including air entering the bloodstream and blood loss due to clotting or accidental disconnection of the blood tubing set. Certain risks are unique to the home. Treatments at home are done without the presence of medical personnel and on-site technical support. Patients and their partners must be trained on what to do and how to get medical or technical help if needed.
Additional Risks Associated with Nocturnal Home Hemodialysis Therapy
The NxStage System One may be used at night while the patient and care partner are sleeping. Certain risks associated with hemodialysis treatment are increased when performing nocturnal therapy due to the length of treatment time and because therapy is performed while the patient and care partner are sleeping. These risks include, but are not limited to, blood access disconnects and blood loss during sleep, blood clotting due to slower blood flow or increased treatment time or both, and delayed response to alarms when waking from sleep. Ancillary anticoagulant infusion pumps and fluid leak detection devices may be used to decrease certain risks for home hemodialysis treatments performed at any time, but NxStage requires the use of fluid leak detectors to identify leaks from the vascular access, Cycler and Cartridge when performing nocturnal therapy with the NxStage System One.
About the NxStage System One The NxStage System One is the first and only truly portable hemodialysis system cleared specifically by the FDA for home hemodialysis and home nocturnal hemodialysis. Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy. When combined with the NxStage PureFlow SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid on demand. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, including while they are sleeping - at home or on vacation and at a medically appropriate treatment frequency. In addition, NxStage's Nx2Me Connected Health platform collects important NxStage System One and patient information for flexible viewing, monitoring and reporting that may improve patient management and simplify alternative site care. http://www.nxstage.com/.
About NxStage Medical NxStage Medical Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the Company's website at www.nxstage.com.
Forward-Looking Statements This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter June 30, 2015. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.